If they need JMP to pull that $2.64 deal together, management should forego all salary and bonuses for this year. That's a pathetic effort for an approved drug and a couple of potential pieces in the pipeline. Obviously bargaining for a deal when you've spent the last year dismantling the company to a point where you have zero bargaining power might not have been a prudent fiduciary choice from Walbert and the board.
Market Data 
Markets 
AI
